Perseon Announces Pricing of $5.2 Million Public Offering and Listing of Warrants on NASDAQ

SALT LAKE CITY, July 30, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (NASDAQ:PRSN) (NASDAQ:PRSNW) ("Perseon" or the "Company"), a leading provider of medical systems that utilize energy to treat cancer, today announced the pricing of an underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase 11,500,000 shares of common stock, at an offering price of $0.90 per share and two warrants. The warrants have a per share exercise price of $0.99, are exercisable immediately, and expire five (5) years from the date of issuance. The shares are traded on The NASDAQ Capital Market under the symbol "PRSN". The warrants will begin trading on The NASDAQ Capital Market on July 30, 2015 under the symbol "PRSNW".

The gross proceeds to the Company from this offering are expected to be $5.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering are being sold by the Company.

The offering is expected to close on August 4, 2015, subject to customary closing conditions. The Company has also granted the underwriters a 45-day option to purchase up to an additional 862,500 shares of common stock and/or 1,725,000 warrants to cover over-allotments, if any.

Maxim Group LLC is acting as the sole book-running manager for this offering.

A registration statement on Form S-1 relating to the shares and warrants was filed with the Securities and Exchange Commission (SEC) and is now effective. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC's web site at Copies of the final prospectus relating to the offering, when available, may be obtained from the offices of Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174 or via telephone at (212) 895-3685.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Perseon

Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.

CONTACT: Tricia Ross Financial Profiles 310-622-8226

Source:Perseon Corporation